Comparison of corticosteroid binder IB with the alpha-chymotrypsin- and RNase-treated hepatic glucocorticoid receptors.
Rat liver and kidney cytosolic extracts contain the glucocorticoid receptor (binder II) and corticosteroid binder IB, both of which possess the steroid- and DNA-binding domains. Since it has been speculated that the smaller binder IB may be generated from binder II by proteolysis, the chymotrypsin-produced receptor fragment in rat liver cytosol has been compared with binder IB in terms of charge, size and DNA binding characteristics. The [3H]triamcinolone acetonide-receptor complex is converted to a smaller fragment by short term digestion (10 degrees C, 30 min) with 100 micrograms/ml alpha-chymotrypsin. Although the chymotrypsin fragment produced from previously heat-activated binder II and binder IB both exhibit DNA-binding capability, they differ in charge and size. Whereas the alpha-chymotrypsin-treated receptor has a Stokes radius of 30 A and elutes from DEAE-cellulose at 0.06 M potassium phosphate in a linear salt gradient, binder IB has a Stokes radius of 20 A and elutes in the buffer wash of the DEAE-cellulose column. Thus, while binder IB can be resolved from the heat-activated form of the [3H]TA-receptor on DEAE, the heat activated alpha-chymotrypsin product elutes from the anion exchange resin at the same ionic strength as intact activated binder II (i.e. at 0.05 M potassium phosphate), and the unactivated intact receptor elutes at about 0.20 M potassium phosphate. A more extended digestion with alpha-chymotrypsin (24 h, 0 degrees C) results in elimination of the DNA binding site without further reduction of the Stokes radius or change in the elution pattern from DEAE-cellulose. Furthermore, molybdate completely blocks formation of binder IB but does not inhibit the production of the receptor fragment by alpha-chymotrypsin. Treatment of the hepatic [3H]TA-receptor complex with RNase has no effect on the charge, size or DNA binding properties of the bound receptor. These results suggest that RNase does not activate the [3H]TA-receptor complex nor does it produce a IB-like component in the liver cytosol. The present results are consistent with the hypothesis that binder IB is formed in vitro by a process which may not involve proteolytic cleavage or RNase-induced modification of the glucocorticoid receptor (binder II).
D000818:Animals; D055598:Chemical Phenomena; D002627:Chemistry, Physical; D002918:Chymotrypsin / Q000494:pharmacology*; D004247:DNA / Q000378:metabolism; D007668:Kidney / Q000032:analysis*; D008099:Liver / Q000032:analysis*; D008297:Male; D010446:Peptide Fragments / Q000378:metabolism; D051381:Rats; D011919:Rats, Inbred Strains; D011965:Receptors, Glucocorticoid / Q000187:drug effects / Q000378:metabolism*; D011987:Receptors, Steroid / Q000378:metabolism*; D012260:Ribonucleases / Q000494:pharmacology*; D014222:Triamcinolone Acetonide / Q000378:metabolism
D010446:Peptide Fragments; D011965:Receptors, Glucocorticoid; D011987:Receptors, Steroid; D004247:DNA; D012260:Ribonucleases; D002918:Chymotrypsin; D014222:Triamcinolone Acetonide